Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRG EXS
- Development stage
- Preclinical
- Lead developer
- Regenerative Research Group
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical, Intraarticular, Intramuscular, Subcutaneous
01
Overview
RRG EXS is an acellular regenerative biologic developed by Regenesys. It consists of a secretome containing exosomes and over 300 growth factors, designed to provide regenerative signaling for tissue repair. As an acellular therapy, it aims to deliver the therapeutic benefits of stem cell paracrine signaling without the risks associated with live cell transplantation, making it a candidate for various applications in regenerative medicine and tissue repair.
- Brand names
- RRG EXS
- Other names
- RRG EXS SecretomesAcellular secretome plus exosomesSecretome with 300+ growth factors
Beyond the preview
Go deeper on RRG EXS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RRG EXS.